Testing is in progress for optical tests for the early detection of Alzheimer’s disease that show promise in providing early molecular signs of the disease in the eye before Alzheimer’s pathology is present in the brain. This achievement raises hopes that the disease’s advancement could be slowed to a crawl. Lee Goldstein of Brigham and Women’s Hospital and Harvard Medical School, who presented the latest in his research at the recent annual meeting of the Optical Society of America (OSA) in Rochester, N.Y., believes that the tests could become part of a suite of screening methods that could be potentially a routine part of annual physical exams beginning in middle age. And because the testing would likely be relatively inexpensive, physicians would be able to monitor patients year to year for any signs that the disease is present and progressing. The technology could also have additional value clinical testing of new emerging treatments for Alzheimer’s.